1 day+20.80%
1 week+38.89%
Current month+40.93%
1 month+35.61%
3 months+66.43%
6 months+82.25%
1 week 81.9
Extreme 81.9
122
1 month 76
Extreme 76
122
Current year 37.55
Extreme 37.55
122
1 year 37.55
Extreme 37.55
122
3 years 37.55
Extreme 37.55
122
5 years 37.55
Extreme 37.55
122
10 years 37.55
Extreme 37.55
122
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 13/01/2017
Chief Executive Officer - 13/01/2017
Director of Finance/CFO - 23/09/2019
Director TitleAgeSince
Director/Board Member 52 25/07/2019
Chairman - 13/01/2017
Director/Board Member - 23/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
+20.80%+38.89% - - 483M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average +1.48%+4.16%+78.02%+110.46% 26.36B
Weighted average by Cap. -0.87%+0.66%+95.83%+132.95%

Financials

2024 2025
Net sales 803K 25.09K 21.66K 20.37K 18.51K 34.77K 2.39M 35.44K 239K 93.2K 1.2M 94.17K 92.15K 4M 50.29M 1.57M 1.36M 1.28M 1.16M 2.18M 150M 2.22M 14.94M 5.84M 75.14M 5.9M 5.77M 250M
Net income -440M -13.76M -11.88M -11.17M -10.15M -19.06M -1.31B -19.43M -131M -51.11M -658M -51.63M -50.53M -2.19B -1.11B -34.57M -29.85M -28.06M -25.5M -47.91M -3.3B -48.84M -329M -128M -1.65B -130M -127M -5.51B
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
14/08/26 NT$115.00 +20.80% 6,061,484
13/08/26 NT$95.20 +1.38% 1,739,987
12/08/26 NT$93.90 +1.84% 2,841,765
11/08/26 NT$92.20 +10.02% 2,818,076
10/08/26 NT$83.80 +1.21% 831,423
  1. Stock Market
  2. Stocks
  3. 7871 Stock